Codexis, Inc.

Industry

  • Biotechnology
    • Large Molecule
    • Antisense, Oligonucleotides
    • Synthesis Technologies, Production Processes
    • Drug Discovery Technologies
      • Bioinformatics
  • Pharmaceuticals
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools

Other Names/Subsidiaries

  • BioCatalytics
See more in Biomedtracker

Latest on Codexis, Inc.

Scrip

Finance Watch: Vicebio Adds To 2024’s Mega-Round Total With $100m Series B

 
• By Mandy Jackson and Elizabeth Cairns

London-based vaccine company Vicebio Ltd. has become the 17th company this year to raise a nine-figure series B round, according to Evaluate data. TCGX led its $100m series B venture capital round,

Scrip

Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sionna Gets CF Compounds AbbVie License

Scrip

Scrip Asks…What Does 2024 Hold For Biopharma? Part 3: Manufacturing And Supply

 
• By Joseph Haas

Drug access and supply-chain issues have remained challenging in the aftermath of the COVID-19 pandemic, while increasing research and development in the cell and gene therapy fields are expected to y

Scrip

Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success

 
• By Mandy Jackson

UroGen Pharma, Ltd. anticipated filing for US Food and Drug Administration approval in 2024 for UGN-102 in the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMI